| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Atpenin A5 has IC50 values of 8.3, 9.3, and 8.5 nM, respectively, for its cytostatic effects on cardiomyocytes, mitochondria, and mitochondrial particles (SMP). Manhattan complex II chip Atpenin A5 (AA5) is a powerful chip. In isolated cardiomyocytes, atpenin A5 (1 nM) mimics reperfusion (IR) injury and inhibits mKATP channel activation [1].
|
|---|---|
| ln Vivo |
In the postpartum heart following myocardial infarction (MI), inhibition of succinate dehydrogenase by Atpenin A5 promotes cardiomyocyte mitosis and regeneration; in contrast to heart disease, the myocardium in the myocardial infarction area injected with Atpenin A5 becomes thicker and scars are significantly reduced [2]. Atpenin A5 is a valid benchmark for succinate dehydrogenase (SDH).
|
| Animal Protocol |
Animal/Disease Models: Neonatal mice [2]
Doses: 100 μg/kg Route of Administration: Daily injection Experimental Results: Myocardial thickness in the infarct area was Dramatically increased and scar size was diminished compared with the control group. |
| References |
|
| Additional Infomation |
Atpenin A5 has been reported in Streptomyces with data available.
|
| Molecular Formula |
C15H21NO5CL2
|
|---|---|
| Molecular Weight |
366.23694
|
| Exact Mass |
365.079
|
| CAS # |
119509-24-9
|
| Related CAS # |
119509-24-9;
|
| PubChem CID |
54676868
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
532.6±50.0 °C at 760 mmHg
|
| Flash Point |
275.9±30.1 °C
|
| Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
| Index of Refraction |
1.534
|
| LogP |
-0.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
23
|
| Complexity |
544
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C[C@@H](C[C@H](C)C(=O)C1=C(C(=C(NC1=O)OC)OC)O)[C@H](CCl)Cl
|
| InChi Key |
OVULNOOPECCZRG-CIUDSAMLSA-N
|
| InChi Code |
InChI=1S/C15H21Cl2NO5/c1-7(9(17)6-16)5-8(2)11(19)10-12(20)13(22-3)15(23-4)18-14(10)21/h7-9H,5-6H2,1-4H3,(H2,18,20,21)/t7-,8-,9-/m0/s1
|
| Chemical Name |
3-[(2S,4S,5R)-5,6-dichloro-2,4-dimethylhexanoyl]-4-hydroxy-5,6-dimethoxy-1H-pyridin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~273.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.83 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7304 mL | 13.6522 mL | 27.3045 mL | |
| 5 mM | 0.5461 mL | 2.7304 mL | 5.4609 mL | |
| 10 mM | 0.2730 mL | 1.3652 mL | 2.7304 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
